



## Cardiac Electrophysiology and Pharmacology

Guest Editors:

### Dr. Norbert Nagy

Department of Pharmacology  
and Pharmacotherapy, Albert  
Szent-Györgyi Medical School,  
University of Szeged, 6721  
Szeged, Hungary

### Dr. Norbert Jost

Department of Pharmacology  
and Pharmacotherapy, Albert  
Szent-Györgyi Medical School,  
University of Szeged, 6721  
Szeged, Hungary

Deadline for manuscript  
submissions:

**closed (30 September 2023)**

### Message from the Guest Editors

Cardiac arrhythmia is a leading cause of morbidity and mortality; therefore, large efforts in cardiac research have gone into finding appropriate antiarrhythmic drugs in the past few decades. Classical antiarrhythmic therapy includes the application of several  $\text{Na}^+$ ,  $\text{K}^+$ , and  $\text{Ca}^{2+}$ -channel blockers. However, the pharmacological interventions are still hampered because the compounds often exert lack of selectivity and/or proarrhythmic side-effects. A further important aspect of the unsatisfactory pharmacological treatments is the lack of sufficient knowledge of the underlying mechanisms in several diseases. Better understanding of cardiac electrophysiology, both in health and in disease, could improve the effectiveness of the pharmacological treatments and may decrease the proarrhythmic risk.

This Special Issue is designed for those fields of cardiac electrophysiology, pathophysiology, and pharmacology that are critically important to improve the efficacy and safety of antiarrhythmic treatment.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)